Radnoff O D, Saito H
Proc Soc Exp Biol Med. 1975 Jan;148(1):177-82. doi: 10.3181/00379727-148-38500.
Exposure of purified Hageman factor (HF, Factor XII) to phenylglyoxal hydrate (PHG), an agent reacting with arginine residues in protein, inhibited its coagulant properties upon subsequent exposure of negatively charged agents. Once HF had been exposed to kaolin or ellagic acid, however, subsequent addition of PHG was much less inhibitory. PHG had no effect upon the ability of HF to bind to negatively charged surfaces. PGH also inhibited preparations of activated PTA (Factor XI) and thrombin, and, when incubated with plasma, reduced the titer of coagulable fibrinogen, PTA Christmas factor (Factor IX), antihemophilic factor (Factor VIII), Factor VII, Stuart factor (Factor X), proaccelerin (Factor V) and prothrombin (Factor II), and to a lesser degres, HF.
将纯化的Hageman因子（HF，凝血因子XII）暴露于苯乙二醛水合物（PHG，一种与蛋白质中的精氨酸残基发生反应的试剂），在随后暴露于带负电荷的试剂时会抑制其凝血特性。然而，一旦HF暴露于高岭土或鞣花酸，随后添加PHG的抑制作用就小得多。PHG对HF结合带负电荷表面的能力没有影响。PGH还抑制活化PTA（凝血因子XI）和凝血酶的制剂，并且在与血浆一起孵育时，会降低可凝固纤维蛋白原、PTA圣诞因子（凝血因子IX）、抗血友病因子（凝血因子VIII）、凝血因子VII、斯图尔特因子（凝血因子X）、前加速素（凝血因子V）和凝血酶原（凝血因子II）的效价，对HF的影响较小。
